CDK4 and breast carcinoma: To assess the impact of elevating CIN on CDK4/6i efficacy, we utilized two diverse cell lines with median rates of aneuploidy, MDA-MB-231, a model of TNBC, and MCF7, a model of ER+ breast cancer.